Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features.
CD163 macrophages
CD39
FOXP3
PD-1
TIM3
endometriosis
endometriosis-associated ovarian cancer
tumour-infiltrating lymphocytes
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jul 2023
28 Jul 2023
Historique:
received:
19
06
2023
revised:
19
07
2023
accepted:
24
07
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
the association between ovarian endometriosis (OE) and endometriosis-associated ovarian cancer (EAOC) is extensively documented, and misfunction of the immune system might be involved. The primary objective of this study was to identify and compare the spatial distribution of tumour-infiltrating lymphocytes (TILs) and tumour-associated macrophages (TAMs) in OE and EAOC. Secondary objectives included the analysis of the relationship between immunosuppressive populations and T-cell exhaustion markers in both groups. TILs (CD3, CD4, and CD8) and macrophages (CD163) were assessed by immunochemistry. Exhaustion markers (PD-1, TIM3, CD39, and FOXP3) and their relationship with tumour-associated macrophages (CD163) were assessed by immunofluorescence on paraffin-embedded samples from we observed a predominantly intraepithelial CD3+ distribution in OE but both an intraepithelial and stromal pattern in EAOC ( the dysregulation of TILs, TAMs, and T-cell exhaustion might play a role in the malignization of OE to EAOC.
Sections du résumé
BACKGROUND
BACKGROUND
the association between ovarian endometriosis (OE) and endometriosis-associated ovarian cancer (EAOC) is extensively documented, and misfunction of the immune system might be involved. The primary objective of this study was to identify and compare the spatial distribution of tumour-infiltrating lymphocytes (TILs) and tumour-associated macrophages (TAMs) in OE and EAOC. Secondary objectives included the analysis of the relationship between immunosuppressive populations and T-cell exhaustion markers in both groups.
METHODS
METHODS
TILs (CD3, CD4, and CD8) and macrophages (CD163) were assessed by immunochemistry. Exhaustion markers (PD-1, TIM3, CD39, and FOXP3) and their relationship with tumour-associated macrophages (CD163) were assessed by immunofluorescence on paraffin-embedded samples from
RESULTS
RESULTS
we observed a predominantly intraepithelial CD3+ distribution in OE but both an intraepithelial and stromal pattern in EAOC (
CONCLUSIONS
CONCLUSIONS
the dysregulation of TILs, TAMs, and T-cell exhaustion might play a role in the malignization of OE to EAOC.
Identifiants
pubmed: 37569458
pii: ijms241512083
doi: 10.3390/ijms241512083
pmc: PMC10418839
pii:
doi:
Substances chimiques
Hepatitis A Virus Cellular Receptor 2
0
Programmed Cell Death 1 Receptor
0
CD3 Complex
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto Carlos III
ID : PI20/01368
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Hum Reprod Update. 2019 Sep 11;25(5):564-591
pubmed: 31424502
Oncoimmunology. 2019 Mar 28;8(6):e1593811
pubmed: 31069161
Cancers (Basel). 2022 Oct 29;14(21):
pubmed: 36358750
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Cancer Immunol Res. 2022 Nov 2;10(11):1326-1339
pubmed: 36095166
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Am J Obstet Gynecol. 2021 Mar;224(3):284.e1-284.e10
pubmed: 32841629
Trends Mol Med. 2018 Sep;24(9):748-762
pubmed: 30054239
J Pathol. 2022 Apr;256(4):388-401
pubmed: 34897700
Int J Gynecol Cancer. 2022 Aug 1;32(8):1009-1016
pubmed: 35437272
Oncoimmunology. 2017 Jan 6;6(2):e1277308
pubmed: 28344892
Int J Clin Exp Pathol. 2018 Aug 01;11(8):3884-3890
pubmed: 31949776
Cancer Immunol Immunother. 2021 Jul;70(7):1821-1829
pubmed: 33411080
EBioMedicine. 2019 Dec;50:203-210
pubmed: 31761620
Eur J Surg Oncol. 2006 Aug;32(6):597-601
pubmed: 16617003
JCI Insight. 2021 Jan 25;6(2):
pubmed: 33332284
Gynecol Oncol. 2016 Apr;141(1):49-56
pubmed: 27016229
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Fertil Steril. 1997 May;67(5):817-21
pubmed: 9130884
Int Immunol. 2020 May 30;32(6):397-405
pubmed: 32009163
Cancers (Basel). 2021 Jul 30;13(15):
pubmed: 34359755
J Clin Med. 2021 Aug 25;10(17):
pubmed: 34501240
Int J Gynecol Pathol. 2011 Nov;30(6):553-68
pubmed: 21979592
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Oncoimmunology. 2015 Feb 3;4(5):e1002732
pubmed: 26155393
Eur J Obstet Gynecol Reprod Biol. 2017 Aug;215:55-61
pubmed: 28601728
Cancer Cell. 2021 Jul 12;39(7):928-944.e6
pubmed: 33961783
Best Pract Res Clin Obstet Gynaecol. 2018 Jul;50:39-49
pubmed: 29506962
Cancer Immunol Immunother. 2009 Mar;58(3):449-59
pubmed: 18791714
Int J Gynecol Cancer. 2022 Aug 1;32(8):1017-1024
pubmed: 35545291
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Cancer Immunol Res. 2015 Aug;3(8):926-35
pubmed: 25957117
Cancer Res. 2012 Sep 1;72(17):4351-60
pubmed: 22798340
Immunol Invest. 2021 May;50(4):372-388
pubmed: 32408782
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Arch Gynecol Obstet. 2016 Sep;294(3):657-64
pubmed: 27358184
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
Fertil Steril. 2022 Jan;117(1):160-168
pubmed: 34656305